GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » ROC (Joel Greenblatt) %

Aptevo Therapeutics (Aptevo Therapeutics) ROC (Joel Greenblatt) % : -433.59% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Aptevo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -433.59%.

The historical rank and industry rank for Aptevo Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

APVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -918.05   Med: -497.25   Max: -257.27
Current: -461.92

During the past 11 years, Aptevo Therapeutics's highest ROC (Joel Greenblatt) % was -257.27%. The lowest was -918.05%. And the median was -497.25%.

APVO's ROC (Joel Greenblatt) % is ranked worse than
55.37% of 1470 companies
in the Biotechnology industry
Industry Median: -339.53 vs APVO: -461.92

Aptevo Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 10.00% per year.


Aptevo Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Aptevo Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics ROC (Joel Greenblatt) % Chart

Aptevo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -614.17 -415.63 -450.53 -533.95 -460.54

Aptevo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -444.10 -468.32 -514.50 -429.00 -433.59

Competitive Comparison of Aptevo Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Aptevo Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's ROC (Joel Greenblatt) % falls into.



Aptevo Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.016) - (4 + 0 + 2.836)
=-4.82

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.163) - (3.984 + 0 + 3.24)
=-5.061

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Aptevo Therapeutics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-25.536/( ( (6.003 + max(-4.82, 0)) + (5.776 + max(-5.061, 0)) )/ 2 )
=-25.536/( ( 6.003 + 5.776 )/ 2 )
=-25.536/5.8895
=-433.59 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptevo Therapeutics  (NAS:APVO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Aptevo Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Traded in Other Exchanges
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121

Aptevo Therapeutics (Aptevo Therapeutics) Headlines

From GuruFocus

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

By ACCESSWIRE ACCESSWIRE 03-30-2023